Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 21, 2026
TickeronGET DAILY SIGNALS
Tilray Brands (TLRY) Shares Decline -35.5% in 30 Days Amid Ongoing Pressures

Tilray Brands (TLRY) Shares Decline -35.5% in 30 Days Amid Ongoing Pressures

Key Takeaways

  • Tilray Brands (TLRY) shares fell roughly 35.5% over the last 30 days, declining from about $2.93 on October 22, 2026, to $1.89 on November 20, 2026.
  • The drop extends a broader downtrend, with the stock down roughly 61% over the last quarter from about $4.84 in late August 2026.
  • Persistent net losses, stalled U.S. cannabis rescheduling, and weaker Canadian cannabis sales have weighed on investor sentiment.
  • Record fiscal first-quarter revenue of $257.1 million (up 23% year over year) was not enough to offset concerns about profitability and sector-wide weakness.
  • Management is reducing costs by consolidating U.S. brewing and Canadian cannabis operations, targeting meaningful annualized savings.
  • For a deeper look at valuation and expectations, explore detailed Price Targets, Earnings, and Forecast pages for TLRY.
  • Interested in automated trading strategies? Browse Tickeron's Trending AI Robots to see curated, top-performing AI trading bots.

A Closer Look at Tilray Brands (TLRY) and Its Position

Tilray Brands (TLRY) is a diversified Canadian cannabis and consumer packaged goods company trading on the Nasdaq. Its operations span medical and recreational cannabis, craft beer and spirits, wellness and hemp-based foods, pharmaceutical distribution in Europe, and an international hospitality segment. Major acquisitions — including craft brewers such as SweetWater and BrewDog, along with beverage and spirits brands — have transformed Tilray into a consumer products platform that generates substantial revenue outside cannabis. The company holds a leading position in the U.K. craft beer market and ranks among the largest U.S. craft brewers, while also operating one of the largest EU GMP-certified medical cannabis footprints in Europe. I follow the stock for its diversified revenue base, its international medical cannabis growth, and its sensitivity to U.S. cannabis policy headlines.

TLRY Stock Price Performance Over the Last 30 Days and Quarter

Over the last 30 days, Tilray shares have declined approximately 35.5%, moving from a closing price of about $2.93 on October 22, 2026, to $1.89 on November 20, 2026. The move was not a single-day shock but a steady grind lower, punctuated by brief rebounds that failed to hold. The stock remained below its 20-day moving average for much of the period, reflecting sustained selling pressure rather than an isolated event. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

The quarterly picture is even steeper. From roughly $4.84 in late August 2026, the stock has fallen about 61%, sliding through the $4 and $3 levels before settling near record-low territory below $2. This multi-month decline places Tilray firmly among the sector's hardest-hit names, with the market capitalization now trading well below annual revenue.

Factors Behind the Recent 30-Day Decline in TLRY

Several factors contributed to the recent decline. First, U.S. federal cannabis rescheduling has stalled, with procedural deadlines passing without a final decision. Because cannabis-linked stocks trade heavily on reform headlines, the absence of progress has removed a key catalyst. Second, the company's fiscal first-quarter 2027 results, reported in early October, showed record net revenue of $257.1 million (up 23% year over year) and beverage revenue up 82% to $101.5 million, but also a net loss of $40 million, or $0.32 per share, and a year-over-year decline in cannabis revenue to $56.1 million from $64.5 million amid Canadian oversupply and price pressure.

Cost-cutting announcements — including consolidating U.S. brewing operations from ten facilities to six (targeting $20 million in annualized savings by fiscal 2028) and restructuring Canadian cannabis production — signaled near-term restructuring but did not halt the slide. Finally, broader sector weakness weighed on the name, with peers such as Canopy Growth (CGC) also under pressure, while volatility around the Organigram-Aurora Cannabis acquisition rippled across Canadian cannabis names.

Drivers of the Broader Quarterly Drop in TLRY

The quarterly decline reflects a larger narrative of fading reform optimism and uneven profitability. Tilray entered fiscal 2027 on the back of record fiscal 2026 revenue and adjusted EBITDA, driven by the BrewDog acquisition and international expansion. European medical cannabis demand, particularly in Germany, has been a bright spot, with EMEA revenue up 71% in the latest quarter. Yet the company remains unprofitable on a net basis, and the Canadian recreational market's oversupply continues to compress margins.

As rescheduling headlines cooled and no near-term U.S. cannabis revenue materialized, investor patience thinned. The stock's fall from above $4.80 in late August to below $2 by mid-November reflects a repricing of growth expectations, with the market now placing greater weight on the company's path to sustainable profitability and cash generation rather than on regulatory catalysts alone.

Key Areas to Watch for TLRY Going Forward

Looking ahead, investors are likely to monitor several factors. Earnings and adjusted EBITDA progress against the company's fiscal 2027 guidance of $68 million to $75 million will be central, as will signs that beverage margins and international medical cannabis sales continue to expand. Balance-sheet execution — including further debt reduction and the results of cost-saving initiatives — will also be closely watched. On the policy side, any movement on U.S. cannabis rescheduling or banking reform could move the entire sector, though Tilray's direct U.S. cannabis exposure remains limited. Competitive pressures in Canada's oversupplied market and the pace of BrewDog integration round out the key risks and catalysts that could shape the stock's direction in the months ahead. From what I see, these elements will determine whether the recent pressure eases.

Using Tickeron AI Tools for Strategy Insights

In my analysis of names like TLRY, I often turn to Tickeron’s AI tools to review automated strategies and compare performance across similar tickers. The platform’s AI Trading Bots section highlights a range of approaches with different holding periods and results, allowing me to evaluate which ones might align with current market conditions without overcomplicating the process. This helps me stay focused on data-driven options while keeping an eye on the broader sector trends.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TLRY

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Momentum Indicator for TLRY turns negative, indicating new downward trend

TLRY saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 79 similar instances where the indicator turned negative. In 73 of the 79 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for TLRY turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 39 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLRY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for TLRY entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +16.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where TLRY advanced for three days, in 166 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

TLRY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.254) is normal, around the industry mean (6.379). P/E Ratio (-2.679) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (0.481) is also within normal values, averaging (183.387).

The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. TLRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TLRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Aurora Cannabis (NASDAQ:ACB), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.46B. The market cap for tickers in the group ranges from 2.12K to 68.49B. MKGAF holds the highest valuation in this group at 68.49B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -8%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was -13%. AKAN experienced the highest price growth at 211%, while PRFX experienced the biggest fall at -39%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -4%. For the same stocks of the Industry, the average monthly volume growth was 37% and the average quarterly volume growth was 47%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 43
P/E Growth Rating: 56
Price Growth Rating: 62
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: 5 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a holding company, whose subsidiaries engages in research, cultivation, processing and distribution of medical cannabis

Industry PharmaceuticalsGeneric

Industry
Biotechnology
Address
265 Talbot Street West
Phone
+1 844 845-7291
Employees
3595
Web
https://www.tilray.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.